A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanomaor a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)
A Study for Patients with Advanced Melanoma, Solid Tumors or Lymphoma Using Study Drug Pembrolizumab
Sponsor: Children's Oncology Group
Enrolling: Male and Female Patients
IRB Number: AAAQ7819
U.S. Govt. ID: NCT02332668
Contact: Luca Szalontay: 212-305-9770 / ls3399@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine if a study drug called pembrolizumab is safe and effective in the treatment of children and adolescents who have advanced melanoma, or advanced, relapsed, or refractory PD-L1 positive malignant solid tumor or other lymphoma, relapsed or refractory classical Hodgkin lymphoma (rrcHL), advanced, relapsed or refractory microsatellite-instability-high (MSI-H) solid tumor. Participants might be at least 6 months ( 3 years rrcHL) to less than 18 years old and able to provide the sample for testing the PD-L1 (programmed cell death ligand 1) purpose from an archival tissue sample or newly obtained biopsy to determine if might qualify for this research study. The participant may be in the study for up to approximately 52 cycles, each study therapy cycle is every 3 weeks.
Nobuko Hijiya, MD
Do You Qualify?
Has your child been diagnosed with any of the above mentioned cancers? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Luca Szalontay